BIOTRONIK Blog

Results from the multicenter CRT‑NEXT Study show that CRT‑DX, BIOTRONIK’s 2-lead CRT-D system, is as safe and effective as conventional 3-lead CRT‑D therapy. The study confirms that most CRT candidates do not develop the need for atrial pacing in the long term and can benefit from therapy with fewer leads. Coordinating Investigator Dr. Mauro Biffi presented the novel data at the American College of Cardiology (ACC) Annual Scientific Session in New Orleans. The results have also been published online in Circulation. CRT‑NEXT is a prospective, multicenter, randomized, controlled, interventional

International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BIOTRONIK today announced the initiation of its global pivotal study evaluating the LivIQ leadless pacemaker system. This next-generation single‑device solution is designed to deliver atrioventricular (AV)-synchrony using advanced electrical far‑field sensing. First implantations within this study have been completed at the Kokura Memorial Hospital in Kitakyushu, Japan and the National Cerebral

BIOTRONIK today announced the launch of the new Acticor Sky and Rivacor Sky device family featuring the world’s first CE-approved left bundle branch area pacing (LBBAP) high-voltage device. These next-generation implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT‑Ds) are now available across CE markets. The first European commercial implant was performed at University Hospital Frankfurt by Dr. Anastasia Falagkari and Prof. Dr. Reza Wakili. The team implanted the CRT-D device Rivacor Sky HF-T in an 87‑year‑old patient with ischemic